133 related articles for article (PubMed ID: 18473931)
1. Novel anti-angiogenic compounds for application in tumor therapy - COP9 signalosome-associated kinases as possible targets.
Braumann C; Tangermann J; Jacobi CA; Müller JM; Dubiel W
Mini Rev Med Chem; 2008 May; 8(5):421-8. PubMed ID: 18473931
[TBL] [Abstract][Full Text] [Related]
2. Novel curcumin- and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells.
Füllbeck M; Huang X; Dumdey R; Frommel C; Dubiel W; Preissner R
BMC Cancer; 2005 Aug; 5():97. PubMed ID: 16083495
[TBL] [Abstract][Full Text] [Related]
3. Taurolidine--a new drug with anti-tumor and anti-angiogenic effects.
Jacobi CA; Menenakos C; Braumann C
Anticancer Drugs; 2005 Oct; 16(9):917-21. PubMed ID: 16162968
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome.
Uhle S; Medalia O; Waldron R; Dumdey R; Henklein P; Bech-Otschir D; Huang X; Berse M; Sperling J; Schade R; Dubiel W
EMBO J; 2003 Mar; 22(6):1302-12. PubMed ID: 12628923
[TBL] [Abstract][Full Text] [Related]
5. Inositol 1,3,4-trisphosphate 5/6-kinase associates with the COP9 signalosome by binding to CSN1.
Sun Y; Wilson MP; Majerus PW
J Biol Chem; 2002 Nov; 277(48):45759-64. PubMed ID: 12324474
[TBL] [Abstract][Full Text] [Related]
6. Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?
Feist M; Huang X; Müller JM; Rau B; Dubiel W
Int J Colorectal Dis; 2014 Jun; 29(6):673-80. PubMed ID: 24728517
[TBL] [Abstract][Full Text] [Related]
7. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
8. The evolving role of taurolidine in cancer therapy.
Neary PM; Hallihan P; Wang JH; Pfirrmann RW; Bouchier-Hayes DJ; Redmond HP
Ann Surg Oncol; 2010 Apr; 17(4):1135-43. PubMed ID: 20039217
[TBL] [Abstract][Full Text] [Related]
9. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
[TBL] [Abstract][Full Text] [Related]
11. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.
Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 2001 Sep; 61(18):6816-21. PubMed ID: 11559556
[TBL] [Abstract][Full Text] [Related]
12. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
Nici L; Monfils B; Calabresi P
Clin Cancer Res; 2004 Nov; 10(22):7655-61. PubMed ID: 15569998
[TBL] [Abstract][Full Text] [Related]
13. Taurolidine specifically inhibits growth of neuroblastoma cell lines in vitro.
Luckert C; Eschenburg G; Roth B; Appl B; Reinshagen K; Bergholz R
J Pediatr Hematol Oncol; 2014 May; 36(4):e219-23. PubMed ID: 24762556
[TBL] [Abstract][Full Text] [Related]
14. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer.
Shanmugam MK; Warrier S; Kumar AP; Sethi G; Arfuso F
Curr Vasc Pharmacol; 2017; 15(6):503-519. PubMed ID: 28707601
[TBL] [Abstract][Full Text] [Related]
15. Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).
Möhler H; Pfirrmann RW; Frei K
Int J Oncol; 2014 Oct; 45(4):1329-36. PubMed ID: 25175943
[TBL] [Abstract][Full Text] [Related]
16. The effect of taurolidine on brain tumor cells.
Stendel R; Stoltenburg-Didinger G; Al Keikh CL; Wattrodt M; Brock M
Anticancer Res; 2002; 22(2A):809-14. PubMed ID: 12014655
[TBL] [Abstract][Full Text] [Related]
17. Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.
Brown A; Shi Q; Moore TW; Yoon Y; Prussia A; Maddox C; Liotta DC; Shim H; Snyder JP
J Med Chem; 2013 May; 56(9):3456-66. PubMed ID: 23550937
[TBL] [Abstract][Full Text] [Related]
18. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines.
Walters DK; Muff R; Langsam B; Gruber P; Born W; Fuchs B
Invest New Drugs; 2007 Aug; 25(4):305-12. PubMed ID: 17458504
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
